ARTICLE | Finance

Joining the in(novation) crowd

Why Chinese biotechs BeiGene, Chi-Med are looking to NASDAQ

October 26, 2015 7:00 AM UTC

At least one buysider thinks the first two innovator Chinese biotechs to attempt a NASDAQ listing will be well-received by U.S. investors thanks to a combination of validating pharma deals and a stable of products against novel or hot cancer targets.

On Oct. 16, both BeiGene Ltd. and Hutchison China MediTech Ltd. (LSE:HCM) filed to raise up to $100 million on NASDAQ...